A physics student whirls a rubber stopper around in a horizontal circle. Suddenly the string breaks. What is the speed of the rubber stopper the moment the string breaks if the radius of the circle is 0.75 m, the mass of the stopper is 45 grams, the angle θ in the diagram is 30 degrees, and the counter weight is 100 grams? Use g = 10 m/s^2.

3. on your graph, the data points between the black squares are data for elements with atomic numbers 3 through 9. locate these elements on your periodic table. what term or description would you use to identify these elements with respect to the periodic table?

5submission this assignment is worth 20 points total. you are required to submit the following by next lab: 1. (3 points) determine the equation for the output angular velocity ω2 = θ˙ 2 as a function of θ1, ω1 = θ˙ 1 and α. you must show all your work to receive credit. 2. (2 points) use the result of problem#1 to plot ω2 over 0 ≤ θ1 ≤ 360deg with ω1 = 360deg/sec. do this for α = {10,30}deg. show the results on the same plot and properly label the axes, title, legend. for this you can use matlab or ms excel. 3. (3 points) determine the equation for the output angular acceleration ω˙ 2 and create a plot similar to the one in problem#2. 4. (10 points) submit plots of the results (ω2 and ω˙ 2) obtained from creo/mechanism and compare them to results of problem#2 and problem#3. note that you should do these comparisons for the two cases with α = {10,30}deg. 5. (2 points) provide a brief explanation of the results. did they match? what are the implications as misalignment angle increases?

Asubject in a clinical research trial experiences a serious, unanticipated adverse drug experience. how should the investigator proceed, with respect to the irb, after the discovery of the adverse event occurrence? a. do not report the adverse drug experience to the irb since it is a common adverse experience. b. report the adverse drug experience to the irb only if there are several other occurrences. c. report the adverse drug experience as part of the continuing review report. d. report the adverse drug experience in a timely manner, in keeping with the irb's policies and procedures, using the forms or the mechanism provided by the irb.